%0 Journal Article
%T Comparative pharmacokinetics and absolute bioavailabilities of two enrofloxacin generic preparations after single intracrop bolus administrations to broiler chickens
%A Abdelrazzag Elmajdoub
%A Abubakr El-Mahmoudy
%A Nasser Ehmeza
%J -
%D 2016
%R 10.14419/ijpt.v4i2.6248
%X The pharmacokinetics and absolute bioavailabilities of two generics of enrofloxacin (ENRO) 10% oral solution formulation at a dose of 10 mg/Kg body weight were compared after single intracrop (i.c.) bolus administrations in reference to single intravenous (i.v.) standard ENRO administration in broilers using a randomized parallel design. The two tested formulations were Enrol£¿ (Medmac£¿, Amman, Jordan) as ENRO-A and Syvaquinol£¿ (Syva£¿, Leon, Spain) as ENRO-B 10% oral solutions. An HPLC assay using pure ENRO base as a standard was used to measure concentrations of ENRO from the selected sources in plasma collected at predetermined time points up to 24 hours. The pharmacokinetic analysis of the C-T data was performed using non-compartmental analysis based on statistical moment theory with the help of computerized WinNonlin program (Version 5.3, Pharsight£¿ Corporation, St. Louis, USA). The maximum plasma concentrations (Cmax) for ENRO-A and ENRO-B were 1.61 ¡À 0.203 and 1.79 ¡À 0.283 ¦Ìg/mL, respectively, attained at time to peak (Tmax) of 2 h. Elimination half-lives (t1/2¦Â) were 8.391 ¡À 0.312 and 8.458 ¡À 0.906 h, respectively. While areas under plasma concentration-time curves (AUC0-¡Þ), and systemic bioavailabilities (F) were 12.744 ¡À 2.951 and 14.354 ¡À 2.85 mg.h/L; and 78.96 ¡À 6.728 and 88.94 ¡À 10.89 % for ENRO-A and ENRO-B, respectively. It could be concluded that despite the superior pharmacokinetic profile of ENRO-B over ENRO-A, however, both generics were within the FDA and EMA bioequivalence acceptance range of 80%¨C125% and thus can be used as interchangeable therapeutic agents in chickens.
%U https://www.sciencepubco.com/index.php/IJPT/article/view/6248